Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

colorectacl cancer

- PMLiVE

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

FDA had placed trial on a temporary hold in September 2020

Roche Basel Switzerland

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Treatment can be administered as an injection instead of an intravenous infusion

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

This is a new option for advanced prostate cancer patients in the US

- PMLiVE

Moderna receives FDA emergency authorisation for its COVID-19 vaccine

Moderna's vaccine is the second to receive FDA approval, following approval of Pfizer/BioNTech’s BNT162b2 vaccine

- PMLiVE

Amgen aims for first KRAS inhibitor approval in the US

Sotorasib is a potential treatment for advanced KRAS G12C-mutated NSCLC

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

- PMLiVE

Moderna scores FDA panel backing for mRNA-based COVID-19 vaccine

EMA also brings forward review meeting of vaccine

- PMLiVE

Novartis receives FDA breakthrough therapy designation for rare disease med

The Swiss pharma company is eyeing approval in PNH and C3G indications

- PMLiVE

FDA experts back safety and efficacy of Moderna’s COVID-19 vaccine

Briefing document published ahead of advisory committee meeting

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links